| Ytd | 3.33% | |
| 1y | 65.27% |
| Open | 110.79 | Prev Close | 110.41 | Low | 110.10 | High | 113.14 | Mkt Cap | 7.59B |
| Vol | 20.61K | Avg Vol | 796.76K | EPS | -3.12 | P/E | N/A | Forward P/E | -148.93 |
| Beta | 1.92 | Short Ratio | 12.80 | Inst. Own | 109.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 91.71 | 200-d Avg | 98.07 | 1yr Est | 139.47 |
RYTM News
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focu
Rhythm Pharma Phase 2 data showed improvements in BMI, body composition, hunger symptoms, and behavi
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweigh
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI o
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focu
"Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweigh
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focu
"This EC authorization is an important step toward making the first new treatment option availab
-- European Commission decision anticipated in second quarter of 2026 --BOSTON, March 26, 2026 (GLOB
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM)
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and
B of A Securities analyst Tazeen Ahmad maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy
PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for
FDA expands Rhythm Pharmaceuticals Imcivree approval for rare hypothalamic obesity, showing strong w
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market O
First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disea
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM)
Playboy (PLBY) shares rise in pre-market trading after reporting better-than-expected Q4 results. Ot
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market O
(Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the headline were update
B of A Securities analyst Tazeen Ahmad maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy
US stock futures down 0.1% as Microvast Holdings Inc reports weak earnings, shares dip 22.9%. Other
Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overwei
Rhythm Pharmaceuticals says EMANATE trial misses goals, despite BMI reduction signals and continued
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and low
-- Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmela
- Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelan
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweigh
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy
Rhythm Pharma shares rise after Phase 3 data show strong BMI drop. FDA decision on obesity drug due
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:RYTM)
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks,
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweigh
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market O
Guggenheim analyst Seamus Fernandez maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and
RBC launches Rhythm Pharma with Outperform, sees $2 billion Imcivree sales by 2030 after Phase 3 obe